Kejadian Perdarahan pada Pasien yang menjalani Intervensi Koroner Perkutan di RS. M Djamil: Studi Retrospektif antara Kelompok HBR dan non-HBR

Muhammad Syukri✉, Muhamad Fakhri
DOI: https://doi.org/10.25077/mka.v46.i2.p311-316.2023

Abstract

Tujuan: Penelitian ini bertujuan untuk mengevaluasi kejadian perdarahan pada pasien yang menjalani PCI antara kelompok high bleeding risk (HBR) dan kelompok non-HBR di RS M Djamil. Metode: Studi potong lintang retrospektif yang diamati pada pasien yang menjalani stenting koroner dari Oktober 2019-Oktober 2020. Pasien dibagi menjadi kelompok HBR dan non HBR berdasarkan kriteria ARC-HBR. Insiden perdarahan dievaluasi dan dibandingkan antara dua kelompok dalam waktu 6 bulan setelah intervensi koroner perkutan (IKP). Perdarahan didefinisikan sebagai BARC 3 dan BARC 5. Hasil: Di antara 288 pasien, kelompok HBR adalah 59 (20,4%) pasien. Kejadian perdarahan lebih tinggi pada kelompok HBR (0 vs 10; P<0,005). Usia lebih tinggi pada kelompok HBR (P=0,002). Jenis kelamin, riwayat medis dan presentasi klinis pasien tidak berbeda antara kedua kelompok. Penggunaan antiplatelet ganda (DAPT) dalam 6 bulan setelah pulang berbeda antara kedua kelompok (P=0,048). Karakteristik prosedur dan jenis stent tidak berbeda antara kedua kelompok. Kesimpulan: Penelitian ini menunjukkan kejadian perdarahan meningkat pada pasien HBR yang menjalani IKP. Usia lebih tinggi pada kelompok HBR. Jenis kelamin, riwayat medis, presentasi klinis, karakteristik prosedur dan jenis stent tampaknya tidak mempengaruhi kejadian perdarahan.
Kata kunci: High Bleeding Risk, Intervensi Koroner Perkutan, Pendarahan

Keywords

High Bleeding Risk, Intervensi Koroner Perkutan, Pendarahan

Full Text:

PDF

References

Ng AK-Y, Ng PY, Ip A, Ling IW-H, Lam L-T, Siu C-W. Incidence, Prediction, and Outcomes of Major Bleeding After Percutaneous Coronary Intervention in Chinese Patients. JACC: Asia. 2022.

Cao D, Mehran R, Dangas G, Baber U, Sartori S, Chandiramani R, et al. Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients. Journal of the American College of Cardiology. 2020;75(21):2711-22.

Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European heart journal. 2019;40(31):2632-53.

Costa F, Garcia-Ruiz V, Licordari R, Fimiani L. The High Bleeding Risk Patient with Coronary Artery Disease. Cardiology Clinics. 2020;38(4):481-90.

Jeong Y-H. “East asian paradox”: challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. Current cardiology reports. 2014;16(5):1-8.

Corpataux N, Spirito A, Gragnano F, Vaisnora L, Galea R, Svab S, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. European heart journal. 2020;41(38):3743-9.

Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S, et al. Application of the academic research consortium high bleeding risk criteria in an all-comers registry of percutaneous coronary intervention. Circulation: Cardiovascular Interventions. 2019;12(11):e008307.

Nakamura M, Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, et al. High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registry. Eurointervention: Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2021;16(14):1154-62.

Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. New England Journal of Medicine. 2015;373(21):2038-47.

Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: Insight from the STOPDAPT-2 trial. Cardiovascular intervention and therapeutics. 2021;36(1):91-103.

Escaned J, Cao D, Baber U, Nicolas J, Sartori S, Zhang Z, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European heart journal. 2021;42(45):4624-34.

Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. Journal of the American College of Cardiology. 2019;73(7):741-54.

Valgimigli M, Cao D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, et al. Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI. Journal of the American College of Cardiology. 2021;78(21):2060-72.

Islam AW, Reza A, Munwar S, Talukder S. High Bleeding Risk (HBR) patients Percutaneous Coronary Intervention-a Challenge to Deal with. Bangladesh Heart Journal. 2021;36(2):133-8.



Bookmark and Share
-->